Common Contracts
17 similar Collaboration Agreement contracts by Cancervax Corp, Diacrin Inc /De/, Exelixis Inc, others
ANDCollaboration Agreement • January 18th, 2006 • pSivida LTD • Laboratory analytical instruments • Georgia
BY AND BETWEENCollaboration Agreement • November 2nd, 2004 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • New York
Exhibit 10.60 COLLABORATION AGREEMENT This Collaboration Agreement, dated as of December 22, 2003 (the "Agreement") is entered into by and among University of Massachusetts, a public institution of higher education of the Commonwealth of Massachusetts...Collaboration Agreement • May 14th, 2004 • Cytrx Corp • Biological products, (no disgnostic substances) • California
EXHIBIT 10.6 GENENTECH CONFIDENTIAL [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406...Collaboration Agreement • November 17th, 2003 • Tolerrx Inc • Pharmaceutical preparations • Delaware
ARTICLE 1 DEFINITIONSCollaboration Agreement • October 24th, 2003 • Cancervax Corp • Biological products, (no disgnostic substances) • California
ARTICLE 1 DEFINITIONSCollaboration Agreement • September 3rd, 2003 • Cancervax Corp • Biological products, (no disgnostic substances) • California
EXHIBIT 10.6 GENENTECH CONFIDENTIAL [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406...Collaboration Agreement • August 26th, 2003 • Tolerrx Inc • Delaware
April 20, 2000 Coulter Pharmaceutical, Inc 600 Gateway Boulevard South San Francisco, California 94080-7014, U.S.A. Attention: Chief Financial Officer RE: Collaboration Agreement Dated October 23, 1998 Between Coulter Pharmaceutical, Inc. and...Collaboration Agreement • March 1st, 2002 • Corixa Corp • Biological products, (no disgnostic substances)
ADDENDUM NO. 1 TO COLLABORATION AGREEMENT (p53 PRODUCTS)Collaboration Agreement • October 4th, 2000 • Introgen Therapeutics Inc • Pharmaceutical preparations
EXHIBIT 10.15 FIRST AMENDMENT TO COLLABORATION AGREEMENT This First Amendment to the Collaboration Agreement (this "Amendment") is entered into as of October __, 1999 by and between EXELIXIS PHARMACEUTICALS, Inc., a Delaware corporation having its...Collaboration Agreement • April 7th, 2000 • Exelixis Inc • Services-commercial physical & biological research
EXHIBIT 10.15 FIRST AMENDMENT TO COLLABORATION AGREEMENT This First Amendment to the Collaboration Agreement (this "Amendment") is entered into as of October __, 1999 by and between EXELIXIS PHARMACEUTICALS, Inc., a Delaware corporation having its...Collaboration Agreement • February 7th, 2000 • Exelixis Inc
BACKGROUNDCollaboration Agreement • November 17th, 1999 • Symyx Technologies Inc • Services-commercial physical & biological research • California
BACKGROUNDCollaboration Agreement • November 12th, 1999 • Symyx Technologies Inc • Services-commercial physical & biological research • California
AGREEMENT BETWEEN CLONTECH LABORATORIES, INC. AND PHASE-1 MOLECULAR TOXICOLOGY, INC.Collaboration Agreement • March 2nd, 1999 • Clontech Laboratories Inc • Biological products, (no disgnostic substances)
EXHIBIT 10.9 COLLABORATION AGREEMENT This Collaboration Agreement ("Agreement") dated as of the 30th day of May, 1997 between HYSEQ, INC., 670 Almanor Avenue, Sunnyvale, California, 94086 U.S.A. (hereinafter "HYSEQ") and THE PERKIN-ELMER CORPORATION,...Collaboration Agreement • June 12th, 1997 • Hyseq Inc • California
EXHIBIT 10.18 COLLABORATION AGREEMENTCollaboration Agreement • February 7th, 1997 • Diacrin Inc /De/ • Biological products, (no disgnostic substances) • Massachusetts
EXHIBIT 10.18 COLLABORATION AGREEMENTCollaboration Agreement • November 13th, 1996 • Diacrin Inc /De/ • Biological products, (no disgnostic substances) • Massachusetts
